Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
27/05/2026 13:00
BRIEF-Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes May 27 (Reuters) - NewcelX AG NCEL.O:
SUBMITS PRE-IND PACKAGE TO THE FDA FOR NCEL-101 FOR THE TREATMENT OF TYPE 1 DIABETES
PRE-IND MEETING WITH FDA SCHEDULED TO ADVANCE NCEL-101 TO FIRST-IN-HUMAN TRIAL
TYPE B PRE-IND MEETING WITH FDA SCHEDULED FOR LAST WEEK OF JUNE
Source text: ID:nGNXc0HPBK
Further company coverage: NCEL.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing